SHAPING THE FUTURE OF INNOVATION
▶ Provide funding in exchange for equity.
▶ Aiming for significant returns as the
company scales.
▶ Higher-risk, higher-reward strategy
fuels innovation, disrupts industries,
and creates market leaders.
▶ Provide funding in exchange for equity.
▶ Aiming for significant returns as the
company scales.
▶ Higher-risk, higher-reward strategy
fuels innovation, disrupts industries,
and creates market leaders.
VISION & MISSION
A form of private equity investment in high-growth startups and emerging businesses that are privately owned.
Prevail Venture Capital believes in the power of innovation to transform industries and improve lives. Our mission is to empower visionary founders with
the strategic capital, expert mentorship, and expansive network they need to scale their businesses and drive meaningful change.
For many founders, securing funding is an exhilarating milestone – often their primary focus at the start. But the true challenge begins afterward: transforming that investment into a thriving, scalable and profitable business. That’s where the right partner (Prevail) becomes invaluable – one who not only believes in their vision but has the expertise to turn it into reality.
We prioritize entrepreneurs, ensuring they maintain control of their vision while accessing critical growth resources.
We go beyond funding, offering hands-on support in scaling operations, leadership development, and strategic planning.
Our team brings decades of experience in private capital, wealth management, and high-growth business development.
We target high-potential companies in healthcare, technology, and consumer sectors, focusing on scalable businesses with a competitive edge.
REDEFINING VENTURE CAPITAL: THE PREVAIL WAY
PREVAIL’S OBJECTIVE IS TO RETURN INITIAL CAPITAL BACK TO INVESTORS AS FAST AS THE FUND ALLOWS, WITH A TARGETED RANGE OF 36 TO 42 MONTHS DEPENDING ON PERFORMANCE
▶ This rapid capital recycling enhances IRR.
▶ Accelerates growth by increasing the velocity of money.
▶ Mitigates risk but also maximizes compounding returns.
FUND OVERVIEW
Prevail Venture Capital is pleased to offer the opportunity to participate in our inaugural fund. Prevail Venture Capital Fund I, LP – a dynamic and diversified investment platform designed to fuel the next generation of groundbreaking companies. The fund targets high-impact, early-stage ventures poised to disrupt industries and redefine the future. You’ll gain exclusive access to visionary entrepreneurs, cutting-edge technologies, and game-changing innovations.
Private Venture Funds come in the form of vintages. Over the past several years, the environment has not been conducive to yield a good harvest. The climate is changing! The fund strategically builds significant positions in high-growth companies, engaging to drive scalable expansion and positioning for high-value exits. Through disciplined execution and strategic partnerships, our goal is to maximize investors’ returns and unlock exceptional value with a focus on returning capital in a shorter timeframe.
The fund targets high-growth sectors- healthcare, technology, consumer products, and emerging opportunities – prioritizing early-stage investments with a goal to maximize investor equity and strategically deploy follow-on capital for sustained value creation.
Kerry Lawing, CEO of Prevail, brings over 35 years of experience in building, scaling, and successfully exiting businesses. Known for his strategic vision and relentless drive, he has a proven track record of accelerating growth and creating lasting impact across multiple industries. His leadership continues to propel Prevail and other entities forward, fostering innovation and long-term value.
Andrew Stafford is a seasoned business leader and financial strategist with a strong background in entrepreneurship and corporate growth. Starting as a 4th generation operator of a family business,
he gained firsthand experience in scaling legacy enterprises. He’s successfully co-launched three startups and led major business units within a $750M company, driving revenue growth in two separate business units from $5M to $30M and $60M to $100M in just three years.
Matthew Burleigh is a Charter Financial Analyst (CFA) with over 25 years of experience in buy-side investment management, focusing on sectors significantly influenced by M&A cycles.
He possesses a deep expertise in financial modeling, valuation analysis, and market forecasting. His proficiency in financial analysis enables him to assess complex investment opportunities, optimize capital allocation, and develop strategic
growth plans.
Timothy Bledsoe is a visionary leader with a strong history of disrupting the healthcare landscape. He was an early member of Salient Surgical, a platform medical device company acquired by Medtronic for $645 million in 2011, and he led the development efforts of a private equity-backed high acuity surgery center business that transacted in 2022. As Co-Founder of NextStage Clinical Research, Tim focuses on bringing cutting-edge research options to patients through partnerships with world-class physicians in their local communities. landscape.
(*) Partners are key relationship consultants and are not direct partners in Prevail Venture Capital Fund I LP or any of its affiliated entities.
Contact Us Today
The information is not an offering to sell a real estate investment. The content is informative in nature and specifics are only available upon request. Investing in real estate involves risk, many times is illiquid, and use should consult your financial professionals before making any investment of this nature.
An offer or solicitation to acquire interests in the investment may only be made by our Private Placement Memorandum (“Memorandum”) in accordance with the terms of all applicable security laws. All information contained herein is subject to and qualified by the contents of the Memorandum. Participation in any securities offering is limited to Accredited investors. Please call to obtain a copy. You must read it before investing. Past performance is no guarantee of future results.
Venture capital is treated as a long-term, complementary allocation rather than a core liquidity source.
Risk profile, structure, sponsor quality, and strategic fit.
Risk is evaluated across structure, execution, concentration, and liquidity.
It supports diversification and long-term objectives when used appropriately.
Allocation is based on liquidity needs, risk tolerance, and time horizon.
Capital should be committed with the expectation of limited or no near-term liquidity.
Through experience review, alignment assessment, and operational evaluation.
Ongoing monitoring focuses on performance, execution, and strategic relevance.
Relative to expectations, risk taken, and role within the portfolio.
By limiting exposure to any single investment, sponsor, or strategy.
Through structured reporting and direct communication.
Time horizon is critical; private capital requires patience.
Tax considerations are evaluated before allocation and throughout the investment lifecycle.
That it is either risk-free or universally appropriate—neither is true.
When liquidity, flexibility, or low risk tolerance are top priorities.
